50340-79-9Relevant articles and documents
Redox-Neutral Photocatalytic C?H Carboxylation of Arenes and Styrenes with CO2
Bergonzini, Giulia,Brandt, Peter,Fricke, Florian,Johansson, Magnus J.,K?nig, Burkhard,Schmalzbauer, Matthias,Svejstrup, Thomas D.
, p. 2658 - 2672 (2020/10/07)
-
MONOCYCLIC, THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF THE SAME
-
Page/Page column 85, (2017/03/21)
The present invention provides monocyclic, thieno, pyrido and pyrrolo pyrimidine compounds. Pharmaceutical compositions comprising one or more of these compounds and optionally comprising a pharmaceutically acceptable salt or hydrate of one or more of the compounds are provided. Preferably, these pharmaceutical compositions further comprise at least one pharmaceutically acceptable carrier. Methods of treating a patient having cancer are provided wherein a therapeutically effective amount of one or more of these compounds or pharmaceutical compositions are administered to the patient.
Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F
Frizler, Maxim,Schmitz, Janina,Schulz-Fincke, Anna-Christina,Gütschow, Michael
supporting information; experimental part, p. 5982 - 5986 (2012/08/14)
A series of dipeptide nitriles with different P3 substituents was designed to explore the S3 binding pocket of cathepsin S. Racemic 7-16 and the enantiopure derivative (R)-22 proved to be potent inhibitors of human cathepsin S and exhibited notable selectivity over human cathepsins L, K, and B. Inhibition of cathepsin F, the functional synergist of cathepsin S, was not observed. The azadipeptide analogue of 22, compound 26, was highly potent but nonselective.